Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Medtech in China – market opportunities

In the second part of our two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the medtech opportunities in China.

The Chinese medical technology (medtech) market is the third largest in the world, and expected to be the second largest worldwide by 2020, with steady growth of more than 10% expected in the coming years.

In 2016, the size of the Chinese medtech market was estimated at almost US$40 million, ranking just behind global leaders the US and Japan. Although the growth of the Chinese medtech segment has slowed from almost 18% to 11-13% in recent years, China remains one of the most attractive markets.

Traditionally, Chinese companies have dominated the low end of the markets, but a few years ago, the government started to launch a number of initiatives promoting innovation in the local medtech industry and changing the industry’s dynamic.

The Innovative Medical Device Assessment office (part of the Chinese Food and Drug Administration) provides grants and loans to local companies to support r&d in segments such as diagnostic imaging and cardiovascular implants, to name a few. These initiatives, together with reforms in reimbursement and tendering processes, have strengthened the competitive position of local companies. Today, this is reflected in an increasing share in the growing mid-portion of the market.

Last year, China spent 5.9% of GDP on health care, of which 3.3% came from public sources. Health care expenditures are expected to increase annually by approximately 3% leading up to 2020.

In total, there are 8,512 acute care hospitals in China (where patients are treated for brief but severe episodes of illness), of which 1,558 are Level 2 hospitals and 6,954 are Level 3 hospitals (Level 1 hospitals are not acute care hospitals). Together these hospitals represent 3,543,443 acute care beds.

Demographics: The size of the Chinese market is the primary factor driving China’s health care market. Effective control, far-reaching mechanisms, and Chinese government regulations for domestic and foreign business activities to create structural improvements and change are in many aspects unique to China’s size.

The Chinese population is aging and chronic diseases are becoming more prevalent. In fact, 330 million Chinese citizens currently have chronic diseases. The Chinese middle class exceeds the population of the US or Western Europe and is facing more lifestyle related diseases. They are also expecting more and better health care services.

Health care reforms and new policies: The share of health care expenses covered by the government will increase from 30% in 2010 to 40% in 2020. Nevertheless, regional inequalities in access to and quality of care will remain. Other changes include cost control through packaged pricing policy, for example, allowing hospitals to charge a fixed amount for a specific procedure. This reimbursement policy results in using fewer and lower cost products. Limited channel markup intends to limit the markup added by distributors, which will affect the partner strategy for many medtech manufacturers.

Shift in provider landscape: The government wants to boost the role of local hospitals (Level 1 hospitals) in low- and mid-range care. They also intend to reroute part of the patient referrals from reference centres (Level 3 hospitals) in Tier 1 cities to Level 2, and 3 hospitals in Tier 2 or 3 cities. Different reimbursement tariffs for the respective types of hospitals have to manage the patient streams. This will challenge the efficiency and profile of the sales and distribution resources of medtech companies.

Separately, the private sector is expected to play a larger role in acute care. Despite the fact that this process is proceeding slower than expected – since no specific action plans have been put into place – the number of private hospitals and clinics is increasing rapidly. Today we see an increasing presence of Chinese private investors in local (Level 1 and 2) hospitals that are operating in a difficult financial context, as well as an increase in military hospitals.

Keeping in mind China’s quintessential vastness of stakeholders, and its large and intricate social and organisational character, its complexity is what typifies it. Accordingly, the reimbursement system that it has developed is appropriate to its profile and is relatively functional and adequate.

With the appropriate insights and market expertise of Chinese policies and market regulations, medtech businesses can perform well in China and both parties can benefit.

Key success factors include:

Prepare. China requires a different preparation and form of operation; companies should be aware of and prepared for this before marketing their product locally.

Build real partnerships. Find a local partner and/or staff who can be trusted, and who trust you, to bridge language barriers, to tap into regional networks and contacts, and to facilitate an understanding and entry into the national/regional business culture.

Understand. Grasp the complexity of the differences in reimbursement, tendering and bidding, buying power, local competition and the like in the different segments in order to optimise pricing and marketing strategy and the adoption/integration of the product into the treatment protocols of Chinese medical practices.

Set priorities. It requires a much more rigorous prioritisation of resources and a specific, dedicated, new and improved sales process.

In addition, new medtech businesses intending to enter the Chinese market must be aware of the market’s unique characteristics and must be cognisant that setting up for commercialisation in China requires a strategy and business model that covers various market segments, regions and types of hospitals.

Moreover, there are other more general aspects such as a rigorous prioritisation of resources and solid sales processes that are important as well. And finally, those entering the market need to have a thorough understanding of the purchase policies of hospitals linked to the acquired technology, the types of treatments offered and the coverage available for those types of treatments.

This piece first appeared on BRINK Asia.

Posted on: 28/07/2017 UTC+08:00


Lilly Asia Ventures, which makes venture capital investments in Asia for global pharmaceutical giant Eli Lilly and Company, has closed LAV Biosciences Fund IV, its fourth fund. It took only two months to reach the hard cap of US$450 million.
Summerset Group, New Zealand’s third-largest listed retirement village operator, has posted a 78% jump in profits for the first half of the year of NZ$90.3 million (US$65.9 million).
Q&M Dental Group, which operates the largest network of private dental outlets in Singapore, has reported a decline in profits for the second quarter of the year, though these are the result of the deconsolidation of two subsidiaries.
Hong Kong-listed Common Splendor International Health Industry Group is currently juggling with two acquisitions in China.
IVD and medical imaging company Yestar Healthcare has said that it is in the preliminary stage of possibly acquiring medical device companies in the northern region of China.
Paragon Care, a leading distributor and manufacturer supplying medical equipment to hospitals, has agreed to acquire Medtek for A$649,000 (US$512,759) shares and cash. The company provides biomedical engineering services and preventative maintenance to the medical, scientific, aged care and allied health clients in the Far North Queensland region.
Hospital operation and management group the Hospital Corporation of China (HCC) plans to buy a 70% stake in an unnamed traditional Chinese medicine private hospital in Zhejiang.
For the first half of the year private specialist healthcare provider Singapore Medical Group (SMG) has reported a massive jump in profits on the back of its move into diagnostics and aesthetics.


Mercer’s Catherine Li explains how companies in China can avoid common pitfalls when they establish employee health management programmes.
Lieven Jacquemyn, PPP international development director at GE Healthcare Singapore, discusses how governments, providers and investors can work together to bring universal health coverage to the region.
Mercer’s Rose Kwan and Heena Sethi explain how employers can better manage their healthcare benefits.
Susann Roth, senior social development specialist, Asian Development Bank, looks at financing mechanisms to meet the third Sustainable Development Goal.
On the back of an ageing population, strong employment growth and the flow of private investment, medical and health care property will emerge as a major asset class in Western Australian’s commercial property markets according to new analysis by independent West Australian commercial property information and research firm, Y Research.
In the second part of our two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the medtech opportunities in China.
In part one of a two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the impact of reforms on medtech in China.
In what is starting to resemble a comedy of errors, Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China, is having to start work yet again for its A-share offering.


HealthInvestor Asia Summit



Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices